Literature DB >> 16335581

Factors associated with poor outcomes in patients with lupus nephritis.

G Contreras1, V Pardo, C Cely, E Borja, A Hurtado, C De La Cuesta, K Iqbal, O Lenz, A Asif, N Nahar, B Leclerq, C Leon, I Schulman, F Ramirez-Seijas, A Paredes, A Cepero, T Khan, F Pachon, E Tozman, G Barreto, D Hoffman, M Almeida Suarez, J C Busse, M Esquenazi, A Esquenazi, L Garcia Mayol, H Garcia Estrada.   

Abstract

The objective of this study was to identify the factors associated with important clinical outcomes in a case-control study of 213 patients with lupus nephritis. Included were 47% Hispanics, 44% African Americans and 9% Caucasians with a mean age of 28 years. Fifty-four (25%) patients reached the primary composite outcome of doubling serum creatinine, end-stage renal disease or death during a mean follow-up of 37 months. Thirty-four percent African Americans, 20% Hispanics and 10% Caucasians reached the primary composite outcome (P < 0.05). Patients reaching the composite outcome had predominantly proliferative lupus nephritis (WHO classes: 30% III, 32% IV, 18% V and 5% II, P < 0.025) with higher activity index score (7 +/- 6 versus 5 +/- 5, P < 0.05), chronicity index (CI) score (4 +/- 3 versus 2 +/- 2 unit, P < 0.025), higher baseline mean arterial pressure (MAP) (111 +/- 21 versus 102 +/- 14 mmHg, P < 0.025) and serum creatinine (1.9 +/- 1.3 versus 1.3 +/- 1.0 mg/dL, P < 0.025), but lower baseline hematocrit (29 +/- 6 versus 31 + 5%, P < 0.025) and complement C3 (54 +/- 26 versus 65 + 33 mg/dL, P < 0.025) compared to controls. More patients reaching the composite outcome had nephrotic range proteinuria compared to controls (74% versus 56%, P < 0.025). By multivariate analysis, CI (hazard ratio [95% CI] 1.18 [1.07-1.30] per point), MAP (HR 1.02 [1.00-1.03] per mmHg), and baseline serum creatinine (HR 1.26 [1.04-1.54] per mg/dL) were independently associated with the composite outcome. We concluded that hypertension and elevated serum creatinine at the time of the kidney biopsy as well as a high CI are associated with an increased the risk for chronic renal failure or death in patients with lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335581     DOI: 10.1191/0961203305lu2238oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  44 in total

1.  Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis.

Authors:  Adnan N Kiani; Tianfu Wu; Hong Fang; Xin J Zhou; Chul W Ahn; Laurence S Magder; Chandra Mohan; Michelle Petri
Journal:  J Rheumatol       Date:  2012-04-15       Impact factor: 4.666

Review 2.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

3.  Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality.

Authors:  Anna Broder; Saakshi Khattri; Ruchika Patel; Chaim Putterman
Journal:  J Rheumatol       Date:  2011-09-01       Impact factor: 4.666

Review 4.  Immunopathology of lupus nephritis.

Authors:  Hans-Joachim Anders; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

5.  Clinicopathological and outcome analysis of adult lupus nephritis patients in China.

Authors:  Yi Tang; XiaoYan Zhang; Ling Ji; XuHua Mi; Fei Liu; LiChuan Yang; Wei Qin
Journal:  Int Urol Nephrol       Date:  2015-01-07       Impact factor: 2.370

6.  Outcome and predictors of kidney disease progression in Puerto Ricans with systemic lupus erythematosus initially presenting with mild renal involvement.

Authors:  Mariely Nieves-Plaza; Ana P Ortiz; Marilú Colón; María J Molina; Lesliane E Castro-Santana; Vanessa E Rodríguez; Angel M Mayor; Luis M Vilá
Journal:  J Clin Rheumatol       Date:  2011-06       Impact factor: 3.517

7.  Outcome of reclassification of World Health Organization (WHO) class III under International Society of Nephrology-Renal Pathology Society (ISN-RPS) classification: retrospective observational study.

Authors:  Jiwon Hwang; Hyung Jin Kim; Ji-Min Oh; Joong Kyong Ahn; Yoo Sun Lee; Jaejoon Lee; Yoon-Goo Kim; Woo-Sung Huh; Jinwon Seo; Eun-Mi Koh; Hoon-Suk Cha
Journal:  Rheumatol Int       Date:  2011-03-27       Impact factor: 2.631

Review 8.  Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care?

Authors:  Lee A Hebert; Brad H Rovin
Journal:  Nephron Clin Pract       Date:  2010-08-03

Review 9.  Treatment of proliferative lupus nephritis: a slowly changing landscape.

Authors:  Vladimir Tesar; Zdenka Hruskova
Journal:  Nat Rev Nephrol       Date:  2010-12-21       Impact factor: 28.314

10.  Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis.

Authors:  H Ding; M Kharboutli; R Saxena; T Wu
Journal:  Clin Exp Immunol       Date:  2016-01-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.